Drugs / Mevrometostat
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06661694 | Apr → Sep 2025 | — | Pfizer | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06392230 | Aug → Nov 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05767905 | Mar → Jun 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03460977 | Apr 2018 → Apr 2028 expected | castration-resistant prostate carcinoma, follicular lymphoma, small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07592910 | Aug 2026 → May 2029 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Prostate Cancer Clinical Trials Consortium | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07028853 | Sep 2025 → Sep 2028 expected | metastatic prostate carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06629779 | Oct 2024 → Dec 2026 expected | castration-resistant prostate carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06551324 | Oct 2024 → Jul 2026 overdue | prostate carcinoma | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mevrometostat | “Single 875 mg dose of mevrometostat standard tablet formulation” NCT06661694 ↗ |
| Known as | PF-06821497 | “A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC),...” NCT03460977 ↗ |
| Action | Inhibit | “new medicine that blocks a protein called enhancer of zeste homolog 2 (EZH2)” PMID 42108644 ↗ May 2026 |
| Modality | Small molecule | — CHEMBL4080228 ↗ |
| Route | Oral | “participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.” NCT03460977 ↗ |
| Target | EZH2 | “new medicine that blocks a protein called enhancer of zeste homolog 2 (EZH2)” PMID 42108644 ↗ May 2026 |